These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32361712)

  • 1. Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT.
    Peric Z; Labopin M; Peczynski C; Polge E; Cornelissen J; Carpenter B; Potter M; Malladi R; Byrne J; Schouten H; Fegueux N; Socié G; Rovira M; Kuball J; Gilleece M; Giebel S; Nagler A; Mohty M
    Bone Marrow Transplant; 2020 Aug; 55(8):1560-1569. PubMed ID: 32361712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
    Kekre N; Marquez-Malaver FJ; Cabrero M; Piñana J; Esquirol A; Soiffer RJ; Caballero D; Terol MJ; Martino R; Antin JH; Lopez-Corral L; Solano C; Armand P; Pérez-Simon JA
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1808-1815. PubMed ID: 27470290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes.
    Oran B; Ahn KW; Fretham C; Beitinjaneh A; Bashey A; Pawarode A; Wirk B; Scott BL; Savani BN; Bredeson C; Weisdorf D; Marks DI; Rizzieri D; Copelan E; Hildebrandt GC; Hale GA; Murthy HS; Lazarus HM; Cerny J; Liesveld JL; Yared JA; Yves-Cahn J; Szer J; Verdonck LF; Aljurf M; van der Poel M; Litzow M; Kalaycio M; Grunwald MR; Diaz MA; Sabloff M; Kharfan-Dabaja MA; Majhail NS; Farhadfar N; Reshef R; Olsson RF; Gale RP; Nakamura R; Seo S; Chhabra S; Hashmi S; Farhan S; Ganguly S; Nathan S; Nishihori T; Jain T; Agrawal V; Bacher U; Popat U; Saber W
    Transplant Cell Ther; 2021 Nov; 27(11):921.e1-921.e10. PubMed ID: 34403791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.
    Duque-Afonso J; Finke J; Ngoya M; Galimard JE; Craddock C; Raj K; Bloor A; Nicholson E; Eder M; Kim O; Valerius T; Snowden JA; Tholouli E; Crawley C; Collin M; Wilson KMO; Gadisseur A; Protheroe R; Wagner-Drouet EM; Savani BN; Spyridonidis A; Ciceri F; Nagler A; Mohty M
    Bone Marrow Transplant; 2024 Feb; 59(2):247-254. PubMed ID: 38040842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.
    Nishimura A; Aoki Y; Ishiwata Y; Ichimura T; Ueyama J; Kawahara Y; Tomoda T; Inoue M; Matsumoto K; Inoue K; Hiroki H; Ono S; Yamashita M; Okano T; Tanaka-Kubota M; Ashiarai M; Miyamoto S; Miyawaki R; Yamagishi C; Tezuka M; Okawa T; Hoshino A; Endo A; Yasuhara M; Kamiya T; Mitsuiki N; Ono T; Isoda T; Yanagimachi M; Tomizawa D; Nagasawa M; Mizutani S; Kajiwara M; Takagi M; Kanegane H; Imai K; Morio T
    J Clin Immunol; 2021 Jul; 41(5):944-957. PubMed ID: 33527309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
    Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
    J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
    Bug G; Labopin M; Niittyvuopio R; Stelljes M; Reinhardt HC; Hilgendorf I; Kröger N; Kaare A; Bethge W; Schäfer-Eckart K; Verbeek M; Mielke S; Carlson K; Bazarbachi A; Spyridonidis A; Savani BN; Nagler A; Mohty M
    Bone Marrow Transplant; 2023 Jun; 58(6):710-716. PubMed ID: 37002412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.
    Kennedy VE; Savani BN; Greer JP; Kassim AA; Engelhardt BG; Goodman SA; Sengsayadeth S; Chinratanalab W; Jagasia M
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1801-1807. PubMed ID: 27377900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
    Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Busulfan-containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study.
    Wang YH; Tien FM; Tsai CH; Huang HH; Liu JH; Liao XW; Tang JL; Yao M; Ko BS
    Cancer Rep (Hoboken); 2022 Mar; 5(3):e1488. PubMed ID: 34196132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.
    Duque-Afonso J; Finke J; Labopin M; Craddock C; Protheroe R; Kottaridis P; Tholouli E; Byrne JL; Orchard K; Salmenniemi U; Hilgendorf I; Hunter H; Nicholson E; Bloor A; Snowden JA; Verbeek M; Clark A; Savani BN; Spyridonidis A; Nagler A; Mohty M
    Bone Marrow Transplant; 2022 Aug; 57(8):1269-1276. PubMed ID: 35568756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
    Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
    J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia.
    Mei M; Tsai NC; Mokhtari S; Al Malki MM; Ali H; Salhotra A; Sandhu K; Khaled S; Smith E; Snyder D; Marcucci G; Forman SJ; Pullarkat V; Stein A; Aldoss I; Nakamura R
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1425-1432. PubMed ID: 32416253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
    J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
    Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Battipaglia G; Labopin M; Mielke S; Ruggeri A; Nur Ozkurt Z; Bourhis JH; Rabitsch W; Yakoub-Agha I; Grillo G; Sanz J; Arcese W; Novis Y; Fegueux N; Spyridonidis A; Giebel S; Nagler A; Ciceri F; Mohty M
    Transplant Cell Ther; 2024 Jan; 30(1):95.e1-95.e10. PubMed ID: 37816471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia.
    Lee SS; Jung SH; Do YR; Kim DS; Lee JH; Park HS; Moon JH; Yi JH; Park Y; Koh Y; Yhim HY; Choi Y; Mun YC; Lee WS; Lee S; Yang DH;
    Yonsei Med J; 2020 Jun; 61(6):452-459. PubMed ID: 32469169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.